Randomized, Open-Label Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone With or Without Exemestane in Postmenopausal Women With ER+ Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy.

Trial Profile

Randomized, Open-Label Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone With or Without Exemestane in Postmenopausal Women With ER+ Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Aug 2017

At a glance

  • Drugs Abiraterone acetate (Primary) ; Exemestane; Prednisolone; Prednisone
  • Indications Advanced breast cancer
  • Focus Biomarker; Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 28 Aug 2017 This trial has been completed in Belgium, according to European Clinical Trials Database
    • 23 Jun 2017 Planned End Date changed from 1 Dec 2018 to 30 Sep 2018.
    • 23 Jun 2017 Planned End Date changed from 1 Dec 2018 to 30 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top